Massachusetts General Hospital

Rachel Wittenberg

MD · Harvard

Residency · Internal Medicine Residency, Massachusetts General Hospital

ORCID 0000-0002-0823-5635

publications

first author

median RCR

0.67

citations

Publications

2025
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG
Nature Communications
2025
Coronary Artery Anomalies in Review: Anomalous Origin, Aneurysms, and Fistulae
Methodist DeBakey Cardiovascular Journal
2025
Adapting Cardiovascular Disease Data to Inform Policy Goals
JACC
2025
Functional Status Trajectory and Survival for Adult Patients Undergoing Heart Transplantation
Clinical Transplantation
2024
Associations With Adverse Postoperative Outcomes in Children Undergoing Atrial Septal Defect Closure in Lower-Resource Settings
JACC: Advances
2024
Preoperative Malnutrition Increases Risk of In‐Hospital Mortality, Major Infection, and Longer Intensive Care Unit Stay After Ventricular Septal Defect Closure
Journal of the American Heart Association
2023
Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome.
JTCVS openRCR 0.515 citesPMID 38204673
2023
Robot-Assisted Laparoscopic Reduction of Gastroesophageal Intussusception With Gastropexy
Annals of Thoracic Surgery Short Reports
2022
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Nature Communications
2021
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.
NPJ vaccinesRCR 0.8613 citesPMID 33397986
2021
The <i>in vitro</i> direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells.
F1000ResearchRCR 0.6711 citesPMID 33976866
2021
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <i>M.tb</i>-Infected Adults.
VaccinesRCR 0.6610 citesPMID 33923628
2020
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
Frontiers in Immunology
2020
Identification of antigens presented by MHC for vaccines against tuberculosis
npj Vaccines

Compiled from public program rosters and open scholarly data (PubMed, OpenAlex, ORCID) with field-normalized impact (NIH iCite RCR). Publication attribution is being actively improved; counts shown are conservative.